within Pharmacolibrary.Drugs.ATC.N;

model N02CD07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.0003283333333333333,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.292,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0006166666666666666,
    Tlag           = 1800
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02CD07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Atogepant is an orally administered, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist, used for the preventive treatment of migraine in adults. It is FDA-approved and is currently used in clinical practice for migraine prevention.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters observed in healthy adult subjects after single and multiple oral doses.</p><h4>References</h4><ol><li><p>Ankrom, W, et al., &amp; Min, KC (2020). Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants. <i>Journal of clinical pharmacology</i> 60(9) 1157–1165. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1610&quot;>10.1002/jcph.1610</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32297990/&quot;>https://pubmed.ncbi.nlm.nih.gov/32297990</a></p></li><li><p>Boinpally, R, et al., &amp; Trugman, J (2023). Pharmacokinetics and Safety of Coadministered Atogepant and Topiramate in Healthy Participants: A Phase 1, Open-Label, Drug-Drug Interaction Study. <i>Clinical pharmacology in drug development</i> 12(10) 1013–1021. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1267&quot;>10.1002/cpdd.1267</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37210713/&quot;>https://pubmed.ncbi.nlm.nih.gov/37210713</a></p></li><li><p>Boinpally, R, et al., &amp; Wangsadipura, V (2024). Pharmacokinetics and Safety of Atogepant Co-administered with Quinidine Gluconate in Healthy Participants: A Phase 1, Open-Label, Drug-Drug Interaction Study. <i>Clinical pharmacology in drug development</i> 13(8) 930–937. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1407&quot;>10.1002/cpdd.1407</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38702918/&quot;>https://pubmed.ncbi.nlm.nih.gov/38702918</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02CD07;
